Andreas Halvorsen's Viking Global Investors significantly cut its position in MEDLINE INC (MDLN) by 57.66% during the second quarter of 2026. According to a quarterly disclosure filed with the SEC, the firm's stake was reduced from 11.43 million shares to 4.84 million. This report reflects trades made between March 31 and June 30, 2026, and was made public on August 14.
During the reporting period, Medline faced significant challenges. On June 2, the U.S. Food and Drug Administration issued a warning letter regarding manufacturing violations, which was followed by a 7.16% decline in the stock price. Subsequently, on August 5, the company's stock fell over 12% after it announced its second-quarter results and lowered its full-year earnings guidance. Several law firms have since launched securities investigations into the company.